Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
12 mars 2025 02h00 HE
|
Zealand Pharma
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with...
Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
10 mars 2025 08h00 HE
|
PMGC Holdings Inc.
Northstrive Biosciences, Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
05 mars 2025 07h52 HE
|
ZyVersa Therapeutics
Inflammasome inhibition in obese animal model with heart failure was cardioprotective & improved metabolic parameters.
Alberta Declares March 4 as World Obesity Day, Recognizing Obesity as a Chronic Disease
04 mars 2025 00h01 HE
|
Obesity Canada
Alberta has become the first province in Canada to officially recognize obesity as a chronic disease.
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight
21 févr. 2025 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight The obesity market size is...
Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River™ Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)
20 févr. 2025 09h55 HE
|
Serenity Medical
HARRISON, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Serenity Medical, a NeuroTechnology Investors (NTI) portfolio company dedicated to the treatment of venous sinus stenosis, today announced the...
UMeWorld Limited Announces Groundbreaking Study Published in the Journal of Lipid Research, Highlighting the Benefits of Low Triglyceride DAGola Cooking Oil for Athletes
18 févr. 2025 08h00 HE
|
UMeWorld Limited
UMeWorld announces groundbreaking study on DAGola oil, showing benefits in reducing uric acid and triglycerides for athletes, supporting long-term health.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists
18 févr. 2025 07h00 HE
|
PMGC Holdings Inc.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Pre-Investigational New Drug Meeting Submission Request to U.S. Food and Drug A
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
06 févr. 2025 08h30 HE
|
Wave Life Sciences USA, Inc.
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation)...
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
05 févr. 2025 16h05 HE
|
Rani Therapeutics, LLC
- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated...